Efficacy of Fosfomycin in Experimental Osteomyelitis Due to Methicillin-Resistant Staphylococcus aureus

被引：15

作者：

Poeppl, W. ^{[1
]}

Tobudic, S. ^{[1
]}

Lingscheid, T. ^{[1
]}

Plasenzotti, R. ^{[2
]}

Kozakowski, N. ^{[3
]}

Georgopoulos, A. ^{[1
]}

Burgmann, H. ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Internal Med 1, Div Infect Dis & Trop Med, A-1090 Vienna, Austria

[2] Med Univ Vienna, Dept Internal Med 1, Div Biomed Res, A-1090 Vienna, Austria

[3] Med Univ Vienna, Dept Internal Med 1, Clin Inst Pathol, A-1090 Vienna, Austria

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2011年 / 55卷 / 02期

关键词：

URINARY-TRACT; BIOLOGICAL COST; IN-VITRO; COMBINATION; INFECTIONS; BIOFILM; BONE;

D O I：

10.1128/AAC.00881-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The activity of fosfomycin was evaluated in an experimental methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis model. Eighteen rats were treated for 4 weeks with 150 mg of fosfomycin/kg of body weight intraperitoneally once daily or with saline placebo. After treatment, animals were euthanized and the infected tibiae were processed for quantitative bacterial culture. Bone cultures were positive for methicillin-resistant S. aureus in all 9 (100%) untreated controls and in 2 of 9 (22.2%) fosfomycin-treated rats. Thus, fosfomycin treatment was significantly more efficacious than placebo. No development of resistance was observed after the 4-week treatment period.

引用

页码：931 / 933

页数：3

共 23 条

[1]

Alós JI, 2007, REV ESP QUIM, V20, P211

[2] Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model [J].

Cai, Yun ;

Fan, Yan ;

Wang, Rui ;

An, Mao-Mao ;

Liang, Bei-Bei .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (03) :563-566

[3] Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy [J].

Dagan, R ;

Klugman, KP ;

Craig, WA ;

Baquero, F .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (02) :129-140

[4] Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections [J].

Dombrowski, Julia C. ;

Winston, Lisa G. .

JOURNAL OF INFECTION, 2008, 57 (02) :110-115

[5] Fosfomycin: Use beyond urinary tract and gastrointestinal infections [J].

Falagas, Matthew E. ;

Giannopoulou, Konstantina P. ;

Kokolakis, George N. ;

Rafailidis, Petros I. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (07) :1069-1077

[6] Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration [J].

Gould, IM ;

MacKenzie, FM .

JOURNAL OF APPLIED MICROBIOLOGY, 2002, 92 :78S-84S

[7] Emergence of fosfomycin-resistant isolates of shiga-like toxin-producing Escherichia coli O26 [J].

Horii, T ;

Kimura, T ;

Sato, K ;

Shibayama, K ;

Ohta, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :789-793

[8] Macrolide-resistant group a streptococcus - Now in the United States [J].

Huovinen, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (16) :1243-1245

[9] BACTERICIDAL ACTIVITY OF CEFOTAXIME AND FOSFOMYCIN IN CEREBROSPINAL-FLUID DURING THE TREATMENT OF RABBIT MENINGITIS EXPERIMENTALLY INDUCED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].

KAZMIERCZAK, A ;

PECHINOT, A ;

TREMEAUX, JC ;

DUEZ, JM ;

KOHLI, E ;

PORTIER, H .

INFECTION, 1985, 13 :S76-S80

[10] In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance [J].

Marchese, A ;

Gualco, L ;

Debbia, EA ;

Schito, GC ;

Schito, AM .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 :S53-S59

← 1 2 3 →